Cargando…

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703

Detalles Bibliográficos
Autores principales:	Wieduwilt, Matthew, Yin, Jun, Kour, Oudom, Teske, Rebecca, Stock, Wendy, Byrd, Ken, Doucette, Kimberly, Mangan, James, Masters, Gregory, Mims, Alice, Jamieson, Katarzyna, Dinner, Shira, Bseiso, Ali, Uy, Geoffrey, Erba, Harry, Litzow, Mark, Stone, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428395/ http://dx.doi.org/10.1097/01.HS9.0000967380.08838.b7

Ejemplares similares

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022)

Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin
por: Silva, Wellington Fernandes da, et al.
Publicado: (2019)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2023)

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
por: Delea, Thomas E., et al.
Publicado: (2019)

P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
por: Russell-Smith, A., et al.
Publicado: (2022)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
por: Maristany, Sumiko, et al.
Publicado: (2022)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
por: Kebriaei, Partow, et al.
Publicado: (2018)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Aujla, Amandeep, et al.
Publicado: (2019)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin
por: Welch, Mary Alma, et al.
Publicado: (2017)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
por: Fingrut, Warren, et al.
Publicado: (2020)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
por: Rubinstein, Jeremy D., et al.
Publicado: (2023)

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
por: Marks, David I., et al.
Publicado: (2019)

Inotuzumab Ozogamicin Murine Analog–Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses
por: Carvello, Michele, et al.
Publicado: (2012)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases
por: Okura, Miyuki, et al.
Publicado: (2020)

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Chen, Joseph, et al.
Publicado: (2020)

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
por: Ravaioli, Federico, et al.
Publicado: (2021)

Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
por: Song, Jinlin, et al.
Publicado: (2019)

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden
por: van Oostrum, I., et al.
Publicado: (2021)

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
por: Pennesi, Edoardo, et al.
Publicado: (2022)

CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
por: Wintering, Astrid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3r2h7i72h25gtvdgk0p6p0oibk